Enduring Material

• Identify metabolic causes of encephalopathy.
• List the tests that should be performed when considering a metabolic cause of encephalopathy.
• Describe the obstacles that metabolic patients face in their diagnostic odyssey.

10.24.23 Unexplained Encephalopathy: Could the cause be metabolic?

• Mark Korson, MD

• Connecticut Children's Office of Continuing Medical Education designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
• The Connecticut Children's designates this enduring material for a maximum of 1 Hour(s) Attendance w/ No Credit. Participants should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn their required annual part II self-assessment credit in the American Board of Otolaryngology – Head and Neck Surgery's Continuing Certification program(formerly known as MOC). It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of recognizing participation.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1.00 MOC points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit.

Successful completion of this CME activity enables the learner to earn credit toward the CME requirement(s) of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

• MEMORIAL GREENSTEIN LECTURE - 1 Hour(s)

Mark Korson, MD has disclosed a financial relationship with one or more ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Recordati Rare DIseases - Teaching - Relationship Ended
• Aeglea BioTherapeutics - Teaching - Relationship Ended
• Travere Therapeutics - Teaching - Relationship Ended
• HemoShear Therapeutics - Review Panel Member - Relationship Has Not Ended
• Glycomine - Consulting - Relationship Ended
• Eton Therapeutics - Consulting - Relationship Has Not Ended
• Acer Therapeutics - Consulting - Relationship Has Not Ended
• Solace Nutrition - Consulting - Relationship Has Not Ended
• Moderna Therapeutics - Teaching - Relationship Ended
• Tessera Therapeutics - Consulting - Relationship Ended

Any financial relationship that was found to be relevant has been mitigated.

Connecticut Children’s is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Connecticut Children's designates this live activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only credits commensurate with the extent of their participation in the various activities. MOC Part 2: Successful completion of this CME activity, which includes participation in the activity and individual assessment of and feedback to the learner, enables the learner to earn up to 1 MOC points in the American Board of Pediatrics’ (ABP), American Board of Otolaryngology-Head and Neck Surgery’s (ABOHNS), American Board of Anesthesiology (ABA), and the and the American Board of Surgery’s (ABS) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABP MOC credit. • Conflict of Interest Policy: All faculty participating in Continuing Medical Education activities sponsored by Connecticut Children’s are required to disclose to the program audience any actual or perceived conflict of interest related to the content of their presentation. Program planners have an obligation to resolve any actual conflicts of interest and share with the audience any safeguards put in place to prevent commercial bias from influencing the content. Mark Korson, MD has teaching relationships with Recordati Rare Diseases, Aeglea BioTherapeutics, Travere Therapeutics, and Moderna Therapeutics. Dr. Korson is a consultant for Glycomine, Eton Therapeutics, Acer Therapeutics, Solace Nutrition, and Tessera Therapeutics. He is a review panel member for HemoShear Therapeutics. All additional planners, activity director and speaker(s) do not have a financial interest/arrangement or affiliation with any organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation. All relevant financial relationships have been mitigated according to the ACCME guidelines. The speaker(s) will not be discussing the use of any off-label product.

This activity is not commercially supported.

• Connecticut Children's is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Connecticut Children's takes responsibility for the content, quality, and scientific integrity of this CME activity.

75 %

100 %

10/18/2023